Sign in
Enrolling by invitationEarly phase 1

Clinical Safety and Efficacy Evaluation of the Blood-cooling and Stasis-removing Formula as an Adjunct to Atorvastatin in the Treatment of Hemorrhagic Moyamoya Disease.

Key facts

Who runs it
The First Affiliated Hospital with Nanjing Medical University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Enrolling by invitation
Phase
Early phase 1
People taking part
60 people, planned
Started
31 Dec 2024
Expected to end
30 Jun 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Atorvastatin
  • Blood-cooling and Stasis-clearing Formula
  • Blood-cooling and Stasis-clearing Formula Placebo
Record updated
26 October 2026

Who can take part

Age
18 years to 60 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (2)Hide the full registry criteria

Who can take part

  • a) Age: 18-60 years old; b) Meets the Western medical diagnostic criteria for Moyamoya disease. Refer to the recommendations in the "Chinese Expert Consensus on the Diagnosis and Treatment of Moyamoya Disease and Moyamoya Syndrome (2024 Edition)": The diagnosis was confirmed as Moyamoya disease (8B22.B) and stroke (A07.01.01); DSA findings include: stenosis or occlusion of the distal ICA and/or the initial segments of the ACA and/or MCA; abnormal vascular network at the base of the skull in the arterial phase; MRI and MRA findings: stenosis or occlusion of the terminal segment of the ICA and/or the initial segment of the ACA and/or MCA; abnormal vascular network in the basal ganglia (more than 2 obvious flow voids in the basal ganglia on one scan plane, suggesting the presence of an abnormal vascular network); ③ Excluding other subtypes of Moyamoya disease that have been diagnosed as Moyamoya disease; c) Traditional Chinese Medicine diagnostic criteria for Moyamoya disease: It meets the diagnostic criteria for "stroke" with phlegm and blood stasis obstructing the collaterals, and has a dark tongue, white or yellow greasy coating, wiry or slippery or thin and hesitant pulse, etc., and has 2 or more main symptoms or 1 main symptom + 2 secondary symptoms to be diagnosed; The basic treatment has remained stable for nearly one month, and no additional medication is needed; e) Can understand and agree to comply with the testing requirements and limitations

Who cannot take part

  • 1. Individuals with coexisting cognitive impairment or severe mental illness (ICD-10: F20-F48, F60-F69), such as Alzheimer's disease, other neurodegenerative diseases, Parkinson's disease, multiple sclerosis, demyelinating/hereditary central nervous system diseases, neurodevelopmental abnormalities, uncontrollable epilepsy, and other neurological diseases that researchers judge to significantly affect motor or cognitive function; 2. Pregnant women and breastfeeding patients; 3. Individuals with severe dysfunction of organs such as the heart, liver, kidneys, and lungs; individuals with severe congenital malformations (including congenital encephalocele, congenital hydrocephalus, congenital spina bifida, Argyll syndrome, etc., and congenital heart diseases with obvious circulatory and respiratory symptoms such as ventricular septal defect, tetralogy of Fallot, etc.); individuals with hematologic disorders; individuals with severe infections, tumors, etc.; individuals with positive HIV/syphilis/hepatitis B/C serological tests; 4. Currently participating in other drug clinical trials; 5. History of intolerance/allergy to any component of the investigational drug; 6. Hemorrhagic stroke within 12 months prior to enrollment; or a history of infarct-type moyamoya disease or other types of moyamoya disease; 7. Use of medications prohibited under this protocol within 30 days prior to enrollment; presence of alcohol or drug dependence; 8. Carotid/cerebrovascular surgery (including interventional treatment) may be required during the trial

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Moyamoya disease

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Moyamoya disease is a relatively rare chronic cerebrovascular disease, and its exact cause is currently unknown. This disease is characterized by the gradual narrowing or even blockage of important blood vessels in the brain (the terminal portion of the internal carotid artery), while simultaneously forming an abnormal network of small blood vessels at the base of the brain. In cerebral angiography, these abnormal vessels appear as a cloud of "smoke," hence the name "Moyamoya disease." Patients with Moyamoya disease often present with cerebral hemorrhage or cerebral infarction as the initial manifestation, which can seriously affect their quality of life and even endanger their lives.

Read full original descriptionShow less

In recent years, with the development of imaging examinations (such as CT, MRI, and cerebral angiography), more and more patients are being diagnosed in a timely manner. However, because the cause is still unclear, there is currently no specific drug to cure the disease. Clinically, medication is mainly used to prevent thrombosis and stabilize blood vessels, such as commonly used...

Aspirin and atorvastatin are used to reduce the risk of cerebral infarction or cerebral hemorrhage and slow the progression of the disease.

Currently, the main treatment for Moyamoya disease remains surgery (revascularization surgery), which aims to reduce seizures by improving blood supply to the brain. However, surgery has certain limitations, such as being technically challenging, carrying high risks, and potentially leading to postoperative complications, and it still cannot completely stop disease progression.

In Traditional Chinese Medicine (TCM) theory, Moyamoya disease is often associated with "phlegm and dampness" and "blood stasis." Simply put, "phlegm and dampness" and "poor blood circulation" in the body affect the normal blood supply and function of the brain, leading to blood vessel blockage or rupture and bleeding. Therefore, TCM treatment typically focuses on **"promoting blood circulation and removing blood stasis, clearing heat and cooling blood, and unblocking the meridians and opening the orifices"**.

"Liangxue Tongyu Fang" is a traditional Chinese medicine formula primarily used to improve hemorrhagic cerebrovascular diseases. Through the combined effects of various Chinese herbs, this formula may help improve blood circulation, reduce vascular damage, and promote brain function recovery.

Currently, this formula has been used in some hemorrhagic encephalopathy cases and has shown certain therapeutic effects. This study will use clinical research methods to observe the safety (whether it will produce significant adverse reactions) and effectiveness (whether it helps improve the condition or reduce recurrence) of "Liangxue Tongyu Fang" in patients with hemorrhagic moyamoya disease, in order to provide more new options and evidence for the treatment of moyamoya disease.

The 2 groups in the trial

  • Atorvastatin + Blood-cooling and Stasis-clearing FormulaTreatment being tested

    Based on standard Western medicine treatment (as placebo comparator), a modified version of the blood-cooling and stasis-removing formula (200ml per dose, twice a day, one dose each time, a formula agreed upon by Nanjing Municipal Hospital of Traditional Chinese Medicine)+Lipid-lowering drug (atorvastatin, Pfizer, 10mg, one tablet once a day) was used for treatment.

    Treatment: Atorvastatin and Blood-cooling and Stasis-clearing Formula

  • Atorvastatin + Blood-cooling and Stasis-clearing Formula PlaceboPlacebo, for comparison

    Standard Western medical treatment was administered. Upon diagnosis, vital signs were immediately monitored, and imaging examinations including a head CT scan, complete blood count, comprehensive biochemistry panel, and coagulation function tests were completed. Routine Western medical intervention was given, including lipid-lowering drugs (atorvastatin, Pfizer, 10mg once daily, one tablet). A placebo was added accordingly. The placebo was prepared by mixing 10% of the original drug formula with rice and edible flavoring to create a control placebo with similar color, taste, and properties.

    Treatment: Atorvastatin and Blood-cooling and Stasis-clearing Formula Placebo

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT07894640, who can take part
Record updated
26 October 2026